Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘personalized cancer vaccine’

Quote of the Day from Tower Hill Tube station a couple of years ago is rather apt when comparing different cancer therapies

Every novel cancer immunotherapy has its day in the limelight, although it obviously goes without saying we shouldn’t compare them unless in a head-to-head trial.

What if the comparisons are made using the wrong parameters, however?

Well, this just compounds the problem further and does neither product nor company or researchers any justice.

This time around we continue the latest chapter in an story we have been following for several years now before it was really in many people’s conscience.

Sometimes it helps to go back to the beginning to see how far things have come, other times it is more useful to look in a broader context of the space it is competing in.

In this latest installment we attempt a look at both plus offer some commentary on how it could be viewed…


To learn more about the latest immunotherapy data and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

One of the pioneers and leading entrepreneurs in the development of personalised cancer vaccines is Professor Ugur Sahin.

In addition to being CEO of the privately-held biopharmaceutical company, BioNTech, he holds an academic appointment at the University of Mainz and is Managing Director of the translational research institute TRON.

This makes Mainz the perfect location for a cancer immunotherapy conference. It’s also where the Association for Cancer Immunotherapy (CIMT) is located. They were the local organisers of the 3rd annual CRI-CIMT-EATI-AACR cancer immunotherapy conference that we recently attended along with over 1400 people from around the world.

One of the underlying themes of the meeting and the posters was the development of personalised cancer vaccines, which is why we’re doing an extended mini-series based on interviews we did in Germany with leaders in the field.

Prof Sahin is a busy man, but we tracked him down in the poster hall. Here’s a brief excerpt from the impromptu interview he kindly gave to BSB.

Subscribers can log-in to read more of the latest thought leader interview or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!